2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Uterine Cervical Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
6
Stomach Neoplasms
5
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Carcinoma, Renal Cell
4
Advanced Solid Tumors
4
Urinary Bladder Neoplasms
3
Recurrence
3
Melanoma
3
Lung Neoplasms
3
Cholangiocarcinoma
3
Solid Tumor
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Kidney Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Sarcoma
1
Interventions
Rituximab
344
Cyclophosphamide
317
fludarabine phosphate
142
Etoposide
139
Peripheral Blood Stem Cell Transplantation
124
fludarabine
112
Filgrastim
112
Mycophenolic Acid
98
Melphalan
98
Whole-Body Irradiation
90
Vincristine
90
Busulfan
87
Cytarabine
85
Doxorubicin
79
Cyclosporine
76
Tacrolimus
75
Radiotherapy
75
Prednisone
73
Bendamustine Hydrochloride
72
Granulocyte Colony-Stimulating Factor
66
Methotrexate
65
Antilymphocyte Serum
56
Carmustine
54
Dexamethasone
50
Gemcitabine
48
Lenalidomide
46
Bortezomib
43
venetoclax
41
ibritumomab tiuxetan
37
obinutuzumab
36
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
zimberelimab
×
Clear all
NCT04772989
2025-08-28
ARC-12
Arcus Biosciences, Inc.
Phase 1
Completed
94 enrolled